TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03086395
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
Study: NCT00868348
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml infiltration 4 ml intraarticular bolus injection of placebo
Study: NCT00857389
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
Study: NCT00857389
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.
Study: NCT00857389
Drug: Thymoglobulin (ATG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
Study: NCT00857389
Drug: G-CSF (Filgrastim)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
Study: NCT00857389
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
Study: NCT03846765
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period.
Study: NCT04066023
Drug: C213 Microneedle System
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
Study: NCT04458857
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose A or Dose B subcutaneous
Study: NCT03097107
Drug: Saroglitazar Magnesium 1 mg
Normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
Study: NCT03097107
Drug: Saroglitazar Magnesium 2 mg
Normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
Study: NCT03097107
Drug: Saroglitazar Magnesium 4 mg
Normalized name: pitavastatin magnesium 4 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
Study: NCT02197260
Drug: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic antibiotics after sub gingival mechanical debridement
Study: NCT03018834
Drug: ANAKINRA 100 mg/daily subcutaneously
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Study: NCT04107675
Drug: Liposomal Cyclosporine A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study: NCT01552694
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral, 100 mg/day for 2 months
Study: NCT03700411
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine intravenous
Study: NCT03700411
Drug: Piritramid
Normalized name: Piritramida
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramid intravenous
Study: NCT00749645
Drug: FANG(30)
Normalized name: FANG
DrugBank: Gemogenovatucel-T (DB17412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
Study: NCT01965522
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
Study: NCT00735904
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-013736 5 mg tablets orally, twice daily, until disease progression
Study: NCT00735904
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
Study: NCT00502047
Drug: Plantago ovata husk
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766128
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The first arm will be treated by zonisamide
Study: NCT00396201
Drug: G-CSF Plus Plerixafor
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT02500186
Drug: Luseogliflozin
Normalized name: luseogliflozin
DrugBank: Luseogliflozin (DB12214)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
Study: NCT03137615
Drug: local anaesthetic injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
Study: NCT01790503
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00145405
Drug: Lanreotide Autogel and Octreotide LAR
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01766960
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five milligrams of intravenous morphine will be administered.
Study: NCT00413647
Drug: CardioPET
Normalized name: Cardiopet
DrugBank: Cardiopet (DB18913)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01810653
Drug: Macrogol (Transipeg, BAY81-8430)
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to 4 sachets per day based on individual titration
Study: NCT01810653
Drug: Macrogol (Forlax)
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to 4 sachets per day based on individual titration
Study: NCT00857389
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
Study: NCT00683163
Drug: PTH(1-84)
Normalized name: PTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg injected subcutaneously (in the abdomen) daily
Study: NCT00735904
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
Study: NCT00359905
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8 mg daily for 12 weeks
Study: NCT00359905
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg daily for 12 weeks
Study: NCT00003332
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003332
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03204539
Drug: Wilate
Normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
Study: NCT01027611
Drug: proparacaine HCL 0.5% + 4% lidocaine solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01027611
Drug: 3.5% viscous lidocaine gel
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01235559
Drug: bitopertin [RO4917838] level 1
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 1, once a day for 52 weeks
Study: NCT01235559
Drug: bitopertin [RO4917838] level 2
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT00634634
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
Study: NCT00634634
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
Study: NCT04504526
Drug: 68Ga-Pentixafor
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
Study: NCT02640183
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00885703
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally.
Study: NCT00885703
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
Study: NCT00675922
Drug: Sulfamylon 5% and Silver Nitrate Soaks
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
Study: NCT00075400
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03226522
Drug: AXS-05
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AXS-05
Study: NCT03226522
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion
Study: NCT03343795
Drug: oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily
Study: NCT03343795
Drug: intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: every week
Study: NCT01576042
Drug: amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Study: NCT01576042
Drug: sotalol
Normalized name: Sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Study: NCT02004509
Drug: Anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
Study: NCT00635037
Drug: bupivacaine and acupuncture
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week
Study: NCT00645814
Drug: placebo for adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Study: NCT00645814
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Study: NCT00645814
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg at Week 0 and 40 mg weekly through Week 11
Study: NCT02712476
Drug: mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
Study: NCT02712476
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is can be used alone or with mannitol for brain relaxation
Study: NCT00807196
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 250mg/m2 day -21 and day -14 of preparative regimen
Study: NCT00807196
Drug: 90Y ibritumomab tiuxetan (Zevalin)
Normalized name: ibritumomab tiuxetan (90Y)
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.4 mCi/kg IV on day -14 of preparative regimen
Study: NCT00807196
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Study: NCT02433977
Drug: Sodium Nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Study: NCT02433977
Drug: Sodium Nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
Study: NCT03154645
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a diuretic
Study: NCT00651820
Drug: Collagenase Santyl
Normalized name: collagenase Topical Ointment [Santyl]
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel.
Study: NCT02433639
Drug: TH-302 monotherapy
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
Study: NCT03947489
Drug: Sarpogrelate HCL 300mg
Normalized name: amiodarone hydrochloride 300 MG
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose administration in healthy volunteers under fasting condition
Study: NCT04095364
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04095364
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04095364
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00584025
Drug: levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 - 500mg IV q 15 min
Study: NCT01854047
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, Subcutaneous injection
Study: NCT01854047
Drug: Salbutamol/albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation as needed
Study: NCT01854047
Drug: Levosalbutamol/levalbuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation as needed
Study: NCT04456296
Drug: Fortesta
Normalized name: Fortesta
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Study: NCT04456296
Drug: Testim
Normalized name: Testim
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Study: NCT03134222
Drug: Lanraplenib
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tablets administered orally once daily with or without food
Study: NCT03134222
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 mg tablets administered orally once daily with or without food
Study: NCT03134222
Drug: Filgotinib placebo
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablets administered orally once daily with or without food
Study: NCT00054704
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole
Study: NCT00654914
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
Study: NCT02089997
Drug: Sodium Risedronate
Normalized name: Sodium risedronate hydrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium risedronate tablets
Study: NCT00758836
Drug: acetominophen
Normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00758836
Drug: telcagepant
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00592930
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexibly dosed oral olanzapine 2.5 to 15 mg/day